Company news
Imugene Ltd (ASX:IMU) news
Imugene Ltd news releases on 6ix. Latest, Feb 15, 2024: Phase 1 onCARlytics Trial Doses First Intravenous Patient
Press releases — page 2
Phase 1 onCARlytics Trial Doses First Intravenous Patient
February 14, 2024
VAXINIA Phase 1 trial doses patients in higher dose cohorts
January 18, 2024
Phase 1 CF33-hNIS Study Update - Positive Early Signals
January 16, 2024
Imugene and NeoImmuneTech to Improve Cancer Treatments
December 11, 2023
Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial
December 6, 2023
New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS
December 5, 2023
Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine
December 5, 2023
Imugene thrilled as VAXINIA granted FDA Fast Track designation
November 28, 2023
FDA Fast Track Designation Granted for VAXINIA Trial Program
November 27, 2023
Azer-cel Hits Major Milestone in Phase 1b CAR T Trial
November 9, 2023
Phase 1 CF33 VAXINIA Study Update - Positive Early Signals
November 5, 2023
Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study
November 1, 2023
Imugene Phase 1 onCARlytics CD19 virus clinical trial opens
October 25, 2023
Imugene B Cell & OV Platforms Featured at ESMO Congress
October 23, 2023
Azer-cel FDA IND Transferred to Imugene
September 27, 2023
Imugene Closes SPP Raising $18.2 million
September 24, 2023
Imugene PD1-Vaxx Update
September 11, 2023
Imugene Receives Positive Feedback From FDA
September 10, 2023
VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1
September 3, 2023
S&P DJI Announces September 2023 Quarterly Rebalance
September 1, 2023
Preliminary Final Report
August 25, 2023
Imugene completes $35M Placement & Launches c.$30M SPP
August 17, 2023
Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
August 15, 2023
Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy
August 13, 2023
Imugene CF33 Oncolytic Virus Study to be Showcased at SITC
August 2, 2023
Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO
July 24, 2023
Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration
July 20, 2023
Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
July 19, 2023
New Dose Escalation in Phase I Clinical Trial of CHECKvacc
July 6, 2023
HER-Vaxx induced antibodies correlated with tumour reduction
June 29, 2023
Imugene PD1-Vaxx patent extended to 2040
June 28, 2023
Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
June 8, 2023
Imugene doses first combination patient in PD1-Vaxx trial
May 31, 2023
Imugene secures IND approval for first-in-class onCARlytics trial
May 19, 2023
FDA clears Imugene IND for onCARlytics first-in-class study
May 18, 2023
onCARlytics with ARTEMIS T cells show anti-tumour activity
May 17, 2023
onCARlytics with Artemis T cells abstract presented at ASGCT
May 2, 2023
Imugene receives $12.6m R&D tax refund
April 25, 2023
Imugene Images and Follows CHECKVacc in TNBC Patients
April 19, 2023
First patients dosed in IT & IV cohort 3 of VAXINIA trial
April 4, 2023
First Patients Dosed in Combination Study of VAXINIA
March 2, 2023
Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
February 9, 2023
Imugene VAXINIA trial advances to Combination Cohort
February 1, 2023
Imugene Receives Vaxinia Ethics Approval in Australia
January 8, 2023
CHECKVacc Data Presented at the 2022 SABC Symposium
December 8, 2022
First Patient Dosed in VAXINIA Intravenous Cohort 2
December 4, 2022
Imugene onCARlytics with Estrella ARTEMIS T Cells SITC
November 13, 2022
Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
November 11, 2022
Imugene onCARlytics with blinatumomab SITC presentation
November 10, 2022
Europe Patent granted for iNKT Cell Therapy Platform
November 6, 2022